IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. ABBV

Go back to IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.02 -0.07 (0.69%)
Previous Close $10.09    52 Week High $2.18 
Open $10.47    52 Week Low $0.30 
Day High $10.47    P/E N/A 
Day Low $10.02    EPS $-3.32 
Volume 111,951       

TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.02 -0.07 (0.69%)
Previous Close $10.09    52 Week High $2.18 
Open $10.47    52 Week Low $0.30 
Day High $10.47    P/E N/A 
Day Low $10.02    EPS $-3.32 
Volume 111,951